Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling.

@article{Yamagishi2004MinodronateAN,
  title={Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling.},
  author={Sho-ichi Yamagishi and Riichiro Abe and Yosuke Inagaki and Kazuo Nakamura and Hiroshi Sugawara and Daisuke Inokuma and Hideki Nakamura and Tadamichi Shimizu and Masayoshi Takeuchi and Akihiko Yoshimura and Richard Bucala and Hiroshi Shimizu and Tsutomu Imaizumi},
  journal={The American journal of pathology},
  year={2004},
  volume={165 6},
  pages={1865-74}
}
Angiogenesis, a process by which new vascular networks are formed from pre-existing capillaries, is required for tumors to grow, invade, and metastasize. Vascular endothelial growth factor (VEGF), a specific mitogen to endothelial cells, is a crucial factor for tumor angiogenesis. In this study, we investigated whether minodronate, a newly developed nitrogen-containing bisphosphonate, could inhibit melanoma growth and improve survival in nude mice by suppressing the VEGF signaling. We found… CONTINUE READING